


Cell Reports, Volume 28

Supplemental Information

A Key Role for the Ubiquitin Ligase UBR4 in Myofiber Hypertrophy in *Drosophila* and Mice

Liam C. Hunt, Jared Stover, Benard Haugen, Timothy I. Shaw, Yuxin Li, Vishwajeeth R. Pagala, David Finkelstein, Elisabeth R. Barton, Yiping Fan, Myriam Labelle, Junmin Peng, and Fabio Demontis

SUPPLEMENTAL FIGURES AND FIGURE LEGENDS



Supplemental Figure S1. Testing Screen Hits by Transgenic Overexpression. Related to Figure 1.

(A) Representative images of larval VL3/4 muscles with Mef2-GAL4 driving overexpression of some screen hits (*Drosophila* homologs of *Hgs*, *Siah*, and *Usp8*) and known regulators of muscle growth (Insulin Receptor, InR; and PTEN). Converse phenotypes to RNAi-mediated knockdown (Figure 1) are obtained. Scale bar (red bar at bottom right) indicates 100 µm.

(B) Quantification of VL3/4 muscle areas for the genotypes shown in (A). All comparisons are significant ($p < 0.05$) compared to *Mef2 > white^{RNAi}* controls ($n \geq 10$ muscles from > 3 larvae).

(C) qPCR demonstrates significant increased mRNA levels of *Drosophila* *sina*, *Usp8*, and *Hrs* (respectively *Siah*, *Usp8*, and *Hgs*; screen hits shown in A-B) upon transgenic overexpression; $p < 0.05$ and $n = 3$ biological replicates consisting of 5 larvae each.




Fig. S2

Supplemental Figure S2. Testing the Efficacy of siRNAs in C2C12 Myoblasts and Myotubes, and in TA Muscles in Mice. Related to Figures 2 and 5.

(A) Representative images of C2C12 myoblasts transfected with siGLO red demonstrate cellular uptake of the fluorescent siRNAs, as also observed in cultures of C2C12 myotubes (C).

(B) Longitudinal fusion indexes measured over 4 days for myoblasts with candidate gene knockdown ($p < 0.05$ with $n = 3$ biologically replicated cultures). Statistical significance refers to the comparison to the NT siRNA control for that timepoint.


(D) Size of C2C12 myotube cultures transfected with candidate gene siRNAs and starved to induce atrophy. The top dashed line indicates the myotube size for NT control siRNAi under fed conditions. Note that Hgs and Ubr4 siRNAs prevent starvation-induced atrophy. $p < 0.05$ with $n = 3$ biological replicates.

(E) Representative images of tibialis anterior (TA) skeletal muscles following electroporation with siGLO red demonstrate the incorporation of siRNAs into the muscle.

(F) Representative images of UBR4C overexpression in C2C12 myoblasts demonstrate that UBR4 inhibits myotube formation and inhibits myotube growth.

(G) Western blots demonstrating that truncated UBR4 (UBR4C ~100 kDa) is distinguishable from endogenous UBR4 (~600 kDa) and differentially targeted by N- and C-terminal targeting siRNAs for UBR4. For a scheme of UBR4C, see Fig. 5D.

(H) Representative images of *UBR4C*-overexpressing myotubes which are smaller in size in comparison to controls, and are resistant to a N-terminal targeting UBR4 siRNA but not to a C-terminal targeting UBR4 siRNA. These results indicate that UBR4C rescues the myotube hypertrophy induced by UBR4N siRNAs. However, UBR4C is targeted by UBR4C siRNAs and therefore does not rescue the myotube hypertrophy induced by UBR4C siRNAs. Quantification of myotube diameters is shown in (I), with $n = 3$ biological replicates and $p < 0.05$.




Supplemental Figure S3. Analysis of Muscle Strength in UBR4 mKO Mice and Controls. Related to Figures 3 and 4.

(A) Frequency distribution of myofiber sizes by isotype from male UBR4 mKO and wild-type tibialis anterior muscles (Figure 3J-K).


(B) Representative images of soleus muscle cross sections labelled for type 1 (red) and type 2A (green) myofibers. Quantitation of the sizes of different myofiber types indicates that type 2A myofibers are significantly larger in the soleus muscle of UBR4 mKO mice, compared to controls, whereas type 1 myofibers are overall unchanged ($n \geq 7$ mice per group).

(C) Body mass, tibialis anterior (TA) muscle mass, and *in situ* functional force measurements for the TA muscles of wild-type (white) and of UBR4 mKO (pink) female mice after 3 months of tamoxifen-induced recombination ($n \geq 8$ mice per group).



Supplemental Figure S4. Immunoprecipitation of FLAG-tagged UBR4 Target Proteins for Testing their Physical and Functional Interactions with UBR4. Related to Figure 5.

Full blots for all co-immunoprecipitated FLAG-tagged putative UBR4 target proteins. The interaction with endogenous UBR4 was tested together with assessment on whether UBR4 is required for their poly-ubiquitination, by using control and UBR4 siRNAs (SiUBR4).



Supplemental Figure S5. Epistatic Interactions of UBR4 with Target Proteins During Tissue Growth. Related to Figure 6.

(A) Testing genetic interactions of UBR4 with putative UBR4 target proteins in *Drosophila* eyes with UBR4 RNAi driven by GMR-GAL4 concomitantly to control RNAi or to RNAi for a UBR4 target protein.

UBR4 RNAi causes a rounded and rough eye phenotype consistent with overgrowth that can be suppressed epistatically by HAT1 and PCNA RNAi. Similar to UBR4 RNAi, UBE2B RNAi produced an overgrowth phenotype. Conversely, RRAD, LMOD2, and TRIP12 RNAi inhibited eye growth both independently and in combination with UBR4 RNAi. Two different RNAi lines were used for TRIP12 and UBE2B.

(B) Knockdown of the *Drosophila* homologs of HAT1, PCNA, RRAD, LMOD2, and TRIP12 (Hat1, PCNA, Rgk1, tmod, and ctrip, respectively) driven by Mef2-GAL4 reduces muscle growth whereas RNAi for *Drosophila* UBE2B (Ubc6) increases muscle size.

indicates that the majority of RRAD RNAi larvae had either missing VL3/4 muscles or that these muscles were too disrupted to accurately be measured. $p < 0.05$ with $n \geq 3$ larvae.

Supplemental Table S7. List of siRNAs used and their catalogue numbers. Related to the STAR Methods.

ON-TARGET Plus siRNA mouse siRNA	Supplier: Dharmacon	Catalog number
Hgs		L-055516-01
Stam		L-060542-01
Stam2		L-059321-01
Usp8		L-059455-01
Siah1a		L-044891-01
Siah1b		L-044849-01
Siah2		L-041993-01
Ubr4		L-050850-00
March5		L-057048-01
Syvn1		L-041789-01
Narf		L-059561-01
Brap		L-047389-01
Ipo13		L-061248-01
Dnajc21		L-049723-01
Rbbp4		L-047448-01
Trip12		L-053913-01
Usp13		L-047753-01
Chmp3		L-062411-01
Klhl30		L-043614-01
Rbbp7		L-041063-00
Nat9		L-063342-01
Ecd		L-045010-01
Fyb		L-043701-00
Zranb1		L-059888-01
Hat1		L-047665-01
Pyroxd1		L-054188-01
Dym		L-049709-01
Inpp5k		L-040159-01
Pcna		L-048531-00
Ddrgk1		L-167022-00
Cendbp1		L-043931-01
Cdk5rap3		L-046463-01
Ltv1		L-053984-02
Ufl1		L-058635-01
Arfgap3		L-040580-01
Itgb1bp2		L-047746-01
Stub1		L-063143-01
Pdcl		L-044992-01
Clhc1		L-063638-01
Ppp1r27		L-064502-01
Rad		L-049536-01
Aamp		L-051212-01
Prkdc		L-040958-00
Fam160b2		L-047972-01
Cyr61		L-043717-01
Gfpt1		L-062877-01
Atxn10		L-043628-01
Prepl		L-059506-01
Mcmbp		L-060010-01
Ipo8		L-057518-00
Lmod2		L-055604-01
Asb8		L-061037-01
Mt2		L-042685-00
Hectd1		L-041047-00
Asns		L-047839-01
Ube2b		L-060426-00
Dnajal		L-058731-01

Supplemental Table S8. Oligonucleotides used for qRT-PCR. Related to the STAR Methods.

Oligonucleotides			
Gene	Forward sequence	Reverse sequence	Species
Sina	CGGCCACCATTTT ATGCTCG	CCGTTCAACTCC AGGCGATA	<i>Drosophila melanogaster</i>
Hrs	GGCACCTCCAGTT ACCGAAA	TAATCAGTTCCG CCGTAGCC	<i>Drosophila melanogaster</i>
Stam	TTCACGGGATTC GAGACGG	GCACTTGGCGCA TTTTCAGT	<i>Drosophila melanogaster</i>
Sip3	AGACCTGCTTGGC CTTTACC	GGGGGAACGCT CCATAAAGT	<i>Drosophila melanogaster</i>
CG9855	GCTATTCCAGTGG GGCTTGT	TCCTGGCTGAGG TTCGATA	<i>Drosophila melanogaster</i>
CG17991	CCAGGCTTGGGT GAATCCAT	CGTTTGGCATTG TGGACAGG	<i>Drosophila melanogaster</i>
Uby/Usp8	TGTCAGCTGAACC AGTGCAT	ACGAGCCAGAG TACTGGGA	<i>Drosophila melanogaster</i>
Poe/UBR4	TCGGACCTGTCCT CGGTTAT	CGCCAGGATTTG TTCAGTGC	<i>Drosophila melanogaster</i>
Ubc6/UBE2B	GAGTACCCAAAC AAACCGCC	TCGCTCAGCAGT GACTGTAT	<i>Drosophila melanogaster</i>
AlphaTub84b	GTTTGTCAAGCCT CATAGCCG	GGAAGTGTTC CACGCGAC	<i>Drosophila melanogaster</i>
Siah1	ACCTTCTGTTGTC TGTTGAC	ATCGCCGCCTAT GACCATT	<i>Mus musculus</i>
Siah2	CCTGGAAGCTGT GATGTCCC	TGCATCATCACC CAGTCCAC	<i>Mus musculus</i>
Hgs	GGAACTACTGGG AGAAGAA	ATGGGCTGAGA GTCTGTCTC	<i>Mus musculus</i>
Stam	ACTAACCACCAG CACGAAGG	CCACCAGTTGGG ATCACTGT	<i>Mus musculus</i>
Stam2	AGAGGTTGAGAC AGCAACGG	GGTCTGGGAGT CGGGTTTT	<i>Mus musculus</i>
Syvn1	GTGGTGGCTCATG CCTACTA	GATGTACAGGAC TGCCATGCT	<i>Mus musculus</i>
March5	AGTGCAACGCCG AGTACTTA	ATGGCCTACAAC CTGCATCA	<i>Mus musculus</i>
Usp8	ACAGGGAGCCAT CGAAACTG	CATGGTGGCTTG TTTTCCCG	<i>Mus musculus</i>
Ubr4	TGAGTGAGGACA AGGGCAAC	GGGTTGGATCGA ACGAAGGT	<i>Mus musculus</i>
Map1lc3b	GATAATCAGACG GCGCTTGC	CCAGGAGGAAG AAGGCTTGG	<i>Mus musculus</i>
Sqstm1	GAATGTGGGGGA GAGTGTGG	CCTCAATGCCTA GAGGGCTG	<i>Mus musculus</i>
Trim63	ACCTTCTCTCAA GTGCCAAG	TCCCAAAGTCAA TGGCCCTC	<i>Mus musculus</i>
Fbxo32	TGAGCGACCTCA GCAGTTAC	GCGCTCCTTCGT ACTTCCT	<i>Mus musculus</i>
Ubb	GGACGCTTAACC GATGGAGA	GCATTTTGACCT CTTTTCTGCCT	<i>Mus musculus</i>
Ubc	CTGCCCTCCACA CAAAGC	TCTGCATCGTCT CTCTCACG	<i>Mus musculus</i>
Psmal	GGTTGCACTGAA GAGAGCAC	CATCAGCAGTTA GACCCGCA	<i>Mus musculus</i>
Psmal5	ACCAACATCGAG CTAGCCAC	TCGAGGACGGCT CCTTCTTA	<i>Mus musculus</i>

Hat1	ATGCCCTGACCTT TCATCCC	TCATTCACCCGT TTGCCGTA	<i>Mus musculus</i>
Rbbp4	ACGGGCCGCAGG AAACAATA	CAAAGGCCGCTT CCTTGTCAG	<i>Mus musculus</i>
Rbbp7	GAGATCGCGGCG TCTGG	TCAAACATCTCT TACTCGCCA	<i>Mus musculus</i>
Cd101	AGCCGGCAGCAA GAGATTTT	GAAGCTGCGGGT TACCATCT	<i>Mus musculus</i>
Sln	TCTTCAGGAAGTG AAGACAAGCC	TGGTAGGACCTC ACGAGGAG	<i>Mus musculus</i>
Mt2	TCGACCCAATACT CTCCGCT	AGGATCCATCGG AGGCACA	<i>Mus musculus</i>
Aldh3a1	GCGCAAGAATGA ATGGACCTC	TCCTGGGTCTGA CGAGTCTT	<i>Mus musculus</i>
Ppia	GGCCGATGACGA GCC	TGTCTTTGGAAC TTTGTCTGCAA	<i>Mus musculus</i>
Gapdh	CCAGAACATCAT CCCTGCATCC	ATACTTGGCAGG TTTCTCCAGG	<i>Mus musculus</i>
Hprt	GATTAGCGATGA TGAACCAGGTT	TCCAAATCCTCG GCATAATGAT	<i>Mus musculus</i>